Jose-Miguel Yamal, Journey Martinez, Mikala C Osani, Xianglin L Du, Lara M Simpson, Barry R Davis
IMPORTANCE: The long-term relative risk of antihypertensive treatments with regard to mortality and morbidity is not well understood. OBJECTIVE: To determine the long-term posttrial risk of primary and secondary outcomes among trial participants who were randomized to either a thiazide-type diuretic, calcium channel blocker (CCB), or angiotensin-converting enzyme (ACE) inhibitor with up to 23 years of follow-up. DESIGN, SETTING, AND PARTICIPANTS: This prespecified secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a multicenter randomized, double-blind, active-controlled clinical trial, followed up with participants aged 55 years or older with a diagnosis of hypertension and at least 1 other coronary heart disease risk factor for up to 23 years, from February 23, 1994, to December 31, 2017...
December 1, 2023: JAMA Network Open
Hana Poloczková, Jan Krejčí
PURPOSE OF REVIEW: An evidence for lipid lowering therapy in heart failure is briefly summarized in this review. RECENT FINDINGS: Heart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled trials that did not show significant benefit of statins on mortality in these patients...
December 4, 2023: Current Atherosclerosis Reports
Katharina Schütt
PURPOSE OF REVIEW: The following overview article summarizes the most important aspects of diagnosis and screening and provides an overview on the current evidence of glucose-lowering and heart failure treatment in patients with diabetes. RECENT FINDINGS: Patients with diabetes exhibit an increased risk to develop heart failure and the presence of both comorbidities has a major impact on the prognosis of these patients. Thus, it is of utmost importance to detect heart failure in patients with diabetes and to screen all patients with heart failure for the presence of diabetes...
December 4, 2023: Current Heart Failure Reports
Courtney Stanley Sundin, Laura Gomez, Brian Chapman
Amniotic fluid embolism (AFE) is a rare, sudden, and catastrophic complication of pregnancy that can result in cardiopulmonary arrest, potentially leading to death. The pathophysiology of an AFE includes an inflammatory and coagulopathic response due to fetal materials entering maternal circulation with the hallmark triad of symptoms: acute respiratory distress, cardiovascular collapse, and coagulopathy. Management of AFE should include high-quality cardiopulmonary resuscitation, immediate delivery of the fetus if applicable, early intubation to provide adequate oxygenation and ventilation, fluid volume resuscitation, and ongoing evaluation of coagulopathy...
January 2024: MCN. the American Journal of Maternal Child Nursing
Daniel O Kellett, Qadeer Aziz, Jonathan D Humphries, Alla Korsak, Alice Braga, Ana Gutierrez Del Arroyo, Marilena Crescente, Andrew Tinker, Gareth L Ackland, Alexander V Gourine
Heart failure is a major clinical problem, with treatments involving medication, devices, and emerging neuromodulation therapies such as vagus nerve stimulation (VNS). Considering the ongoing interest in using VNS to treat cardiovascular disease it is important to understand the genetic and molecular changes developing in the heart in response to this form of autonomic neuromodulation. This experimental animal (rat) study investigated the immediate transcriptional response of the ventricular myocardium to selective stimulation of vagal efferent activity using an optogenetic approach...
December 4, 2023: Physiological Genomics
Blake Jardin, Jonathan A Epstein
Cardiac fibrosis remains an unmet clinical need that has so far proven difficult to eliminate using current therapies. As such, novel technologies are needed that can target the pathologic fibroblasts responsible for fibrosis and adverse tissue remodeling. mRNA encapsulated in lipid nanoparticles (LNPs) are an emerging technology that could offer a solution to this problem. Indeed, this strategy has already shown clinical success with the mRNA COVID-19 vaccines. In this AJP perspective, we discuss how this technology can be leveraged to specifically target cardiac fibrosis via several complementary strategies...
December 4, 2023: American Journal of Physiology. Cell Physiology
Xiutian Chen, Jiali Wang, Yongda Lin, Kaijin Yao, Yina Xie, Tianbiao Zhou
BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors provide cardiovascular protection for patients with heart failure (HF) and type 2 diabetes mellitus (T2DM). However, there is little evidence of their application in patients with chronic kidney disease (CKD). Furthermore, there are inconsistent results from studies on their uses. Therefore, to explore the cardiovascular protective effect of SGLT2 inhibitors in the CKD patient population, we conducted a systematic review and meta-analysis to evaluate the cardiovascular effectiveness and safety of SGLT2 inhibitors in this patient population...
2023: Frontiers in Endocrinology
Sarita Shrivastva, Stalin Chowdary Bala, Rachana Chennamaneni, Meher Lakshmi Konatam, Venkateswara Rao Pydi, Kuruva Siva Prasad, Sadashivudu Gundeti
Rachana Chennamaneni Trastuzumab, a humanized monoclonal antibody, significantly improves outcomes in HER 2-neu positive breast cancer. The incidence of cardiotoxicity with trastuzumab is approximately 8 to 10%. This study was designed to analyze the incidence and risk factors associated with trastuzumab-related cardiotoxicity in real-world settings. This was a single institutional retrospective analysis of the incidence of trastuzumab-related cardiotoxicity in nonmetastatic HER 2-positive, invasive breast cancer from January 2013 to December 2018...
July 2023: South Asian Journal of Cancer
Hadeel Halalsheh, Ramiz Abu-Hijlih, Taleb Ismael, Ahmad Shehadeh, K J Salaymeh, Mohammad Boheisi, Iyad Sultan
Hadeel Halalsheh Introduction  We implemented new clinical practice guidelines (CPG) for patients with osteosarcoma starting in January 2009. These guidelines were based on standard European and American Osteosarcoma Study regimen, which includes six cycles of doxorubicin with a cumulative dose of 450 mg/m 2 . Aiming to reduce cardiac toxicity at our center, we opted to reduce the cumulative dose of doxorubicin to 375 mg/m 2 . Materials and Methods  This is a retrospective cohort of osteosarcoma patients aged <18 years, treated at our center between 2009 and 2018...
July 2023: South Asian Journal of Cancer
Xiaorong Xu, Jing Cheng, Yeping Zhang, Xin Wang, Mulei Chen, Lin Xu, Wenshu Zhao
BACKGROUND: The efficacy of chronic heart failure (CHF) checklist management in reducing adverse outcomes of heart failure patients is still uncertain. This study explores whether CHF checklist management is more useful than usual care in reducing adverse health outcomes in the medium- and long-term among CHF patients. METHODS: In our prospective study, 132 patients with CHF were randomly assigned to CHF management group and usual care group by random number method...
2023: Therapeutics and Clinical Risk Management
John M Flack, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Sharon G Adler, Linda Fried, Kenneth Jamerson, Robert Toto, Meike Brinker, Alfredo E Farjat, Peter Kolkhof, Robert Lawatscheck, Amer Joseph, George L Bakris
RATIONALE & OBJECTIVE: In FIDELITY, finerenone improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This analysis explored the efficacy and safety of finerenone in Black patients. STUDY DESIGN: Subanalysis of randomized controlled trials. SETTING & PARTICIPANTS: Patients with T2D and CKD. INTERVENTION: Finerenone or placebo. OUTCOMES: Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure; composite of kidney failure, sustained ≥57% estimated glomerular filtration rate (eGFR) decline from baseline maintained for ≥4 weeks, or renal death...
December 2023: Kidney medicine
Rahul N Patel, Akash Sharma, Anand Prasad, Shweta Bansal
Heart failure with preserved ejection fraction (HFpEF) is a heterogenous syndrome with varying phenotypic expression. The phenotype chronic kidney disease (CKD) associated HFpEF is increasing in prevalence globally and is associated with increased morbidity and mortality compared to other HFpEF variants. These 2 conditions share common risk factors, including obesity, diabetes, and metabolic syndrome, as well as similar pathophysiology, including systemic inflammation, oxidative stress, elevated neurohormones, mineralocorticoid-receptor activation, and venous congestion...
December 2023: Kidney medicine
Saud Al Saleh, Mirela Dobre, Sarah DeLozier, Jaime Perez, Nirav Patil, Mahboob Rahman, Nishigandha Pradhan
RATIONALE & OBJECTIVE: The clinical significance of isolated diastolic hypertension in patients with chronic kidney disease (CKD) is unclear. We assessed the prevalence of isolated diastolic hypertension and its association with adverse kidney and cardiovascular outcomes in participants in the Chronic Renal Insufficiency Cohort (CRIC) study. STUDY DESIGN: Prospective cohort study. SETTING & POPULATION: CRIC study participants with complete baseline data on systolic blood pressure (SBP) and diastolic BP (DBP) (N=5,621)...
December 2023: Kidney medicine
Stefan Toggweiler, Lucca Loretz, Mathias Wolfrum, Ralf Buhmann, Jürgen Fornaro, Matthias Bossard, Adrian Attinger-Toller, Florim Cuculi, Justus Roos, Jonathon A Leipsic, Federico Moccetti
BACKGROUND: Motion artifacts in planning computed tomography (CT) for transcatheter aortic valve implantation (TAVI) can potentially skew measurements required for procedural planning. Whether such artifacts may affect safety or efficacy has not been studied. METHODS: We conducted a retrospective analysis of 852 consecutive patients (mean age, 82 years; 47% women) undergoing TAVI-planning CT at a tertiary care center. Two independent observers divided CTs according to the presence of motion artifacts at the annulus level (Motion vs...
November 2023: Structural heart: the journal of the Heart Team
Hayyan Asim Chaudry, Waddah Maskoun
BACKGROUND: Defibrillation threshold (DFT) testing is done to assess whether proper sensing of ventricular fibrillation and adequate safety margin for defibrillation are present in an implantable cardioverter defibrillator (ICD). This case report presents an intuitive method for lowering the DFT. It may be used on a larger scale in other patients with high DFTs when other methods for lowering the DFT (changing medications, adjusting the device, and adding coils) are not feasible or preferable to use...
December 2023: European Heart Journal. Case Reports
Hannah M la Roi-Teeuw, Maarten van Smeden, Geert-Jan Geersing, Olaf H Klungel, Frans H Rutten, Patrick C Souverein, Sander van Doorn
AIMS: Previous studies suggest relatively increased cardiovascular risk after COVID-19 infection. This study assessed incidence and explored individual risk and timing of cardiovascular disease occurring post-COVID-19 in a large primary care database. METHODS AND RESULTS: Data were extracted from the UK's Clinical Practice Research Datalink. Incidence rates within 180 days post-infection were estimated for arterial or venous events, inflammatory heart disease, and new-onset atrial fibrillation or heart failure...
November 2023: Eur Heart J Open
Mario Speranza-Sánchez, Esteban Zavaleta, Sonia Sancho-Zumbado, Juan Carlos Elizondo-Urrutia, Alonso Quirós-Romero, José Chaverri-Fernández, Jonathan García-Montero, Sebastián Arguedas-Chacón
Vericiguat has emerged as a promising add-on therapy for decompensated heart failure with reduced ejection fraction (HFrEF) patients requiring hospitalization or IV diuretic administration. In the VICTORIA trial (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction), vericiguat was demonstrated to significantly reduce mortality and hospitalization rates. However, the effect of vericiguat on patients receiving SGLT2 inhibitors remains uncertain. In this report, we present a complicated case of dilated heart failure receiving low doses of foundational therapy due to a patient's intolerance but still experiencing recurrent hospital readmissions...
October 2023: Curēus
Mohammed M Alsultan, Rabab Alamer, Fatimah Alammar, Wafa Alzlaiq, Abdullah K Alahmari, Ziyad S Almalki, Faisal Alqarni, Dhfer M Alshayban, Fawaz M Alotaibi, Ibrahim M Asiri, Fahad Alsultan, Sawsan M Kurdi, Bassem A Almalki
BACKGROUND: Cardiovascular disease is the leading cause of death and disability worldwide. It is a general term used to describe a group of disorders that affect the heart or blood vessels. This study aimed to evaluate the prevalence and predictors of polypharmacy in patients with heart failure. METHODS: We conducted a cross-sectional study in a tertiary hospital in Saudi Arabia. Data was extracted from an electronic database between January 2019, and December 2022...
December 2023: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
Anna Jeong, Yongwoon Lim, Taewon Kook, Duk-Hwa Kwon, Young Kuk Cho, Juhee Ryu, Yun-Gyeong Lee, Sera Shin, Nakwon Choe, Yong Sook Kim, Hye Jung Cho, Jeong Chul Kim, Yoonjoo Choi, Su-Jin Lee, Hyung-Seok Kim, Hae Jin Kee, Kwang-Il Nam, Youngkeun Ahn, Myung Ho Jeong, Woo Jin Park, Young-Kook Kim, Hyun Kook
Heart failure is a leading cause of death and is often accompanied by activation of quiescent cardiac myofibroblasts, which results in cardiac fibrosis. In this study, we aimed to identify novel circular RNAs that regulate cardiac fibrosis. We applied transverse aortic constriction (TAC) for 1, 4, and 8 weeks in mice. RNA sequencing datasets were obtained from cardiac fibroblasts isolated by use of a Langendorff apparatus and then further processed by use of selection criteria such as differential expression and conservation in species...
December 12, 2023: Molecular Therapy. Nucleic Acids
Trey W Pittman, Xi Zhang, Chamindie Punyadeera, Charles S Henry
Heart failure (HF) is an emerging epidemic and remains a major clinical and public health problem. Advances in the healthcare management of HF may lead to lower morbidity and mortality rates but require diagnostics to guide the process. Current diagnostics/prognostics approaches rely on expensive equipment, centralized facilities and trained personnel, marginalizing healthcare access in developing countries and rural communities. These issues have led researchers to focus on developing portable and affordable diagnostics that can be deployed at the point-of-care (POC)...
February 1, 2024: Sensors and Actuators. B, Chemical
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.